For citations:
Grünwald V., Powles T., Kopyltsov E., Kozlov V., Alonso-Gordoa T., Eto M., Hutson T., Motzer R., Winquist E., Maroto P., Keam B., Procopio G., Wong S., Melichar B., Rolland F., Oya M., Rodriguez-Lopez K., Saito K., McKenzie J., Porta C. Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study. Cancer Urology. 2023;19(4):32-43. (In Russ.) https://doi.org/10.17650/1726-9776-2023-19-4-32-43
Email this article 